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Interest in the biology of the intervertebral disc has grown 
signifi cantly over the past 2 decades, driven mainly by stud-
ies aimed at developing biological therapies for repairing 
degenerate discs (Alini et al. 2002, Sakai and Grad 2015). 
Most interest has focused on cellular therapies, where cells, 
capable of synthesizing appropriate disc tissue, are implanted 
into the damaged tissue to replace resident cells that have died 
or have acquired a degenerative phenotype. This appears to 
be an attractive strategy, and has led to a signifi cant increase 
in information about disc cellular biology. It follows the 
approach used clinically for repairing damaged cartilage 
(Hunziker et al. 2015); however, cell therapy for the disc faces 
more obstacles than that for cartilage repair and has not yet 
entered routine clinical practice. 
In this review, we discuss some of the challenges in suc-
cessful cellular repair of the disc. We fi rst review the function, 
organization, and composition of a normal disc, outline the 
changes that occur in degeneration, and consider how these 
might infl uence function. We then summarize cell therapy 
approaches to repairing the disc in relation to the choice of 
cells and cell support. We outline the challenges facing the 
implanted cells in the degenerate disc, and ask whether these 
therapies can be evaluated in animal models. Finally, we out-
line the important, but often neglected, problem of patient 
selection.  
The disc is complex in structure, composition, 
and function. What are we aiming to repair/
regenerate?
The normal disc
Morphology and composition
The intervertebral discs are large load-bearing cartilaginous 
tissues that lie interspersed between the bony vertebral bodies. 
Morphologically, the disc appears to consist of 2 main regions 
(Figure 1), with an inner, more gelatinous region, the nucleus 
pulposus (or nucleus), encircled by a stiffer, collagenous annu-
lus fi brosus (or annulus), consisting of concentric lamellae. 
The nucleus and annulus are separated from the bone by a thin 
(approx. 1-mm) layer of hyaline cartilage, the cartilage end-
plate; annulus insertions anchor the disc to the bone (Nosikova 
et al. 2012). The normal disc is virtually avascular, with blood 
vessels and nerves being found only in the periphery of the 
annulus. 
The composition and organization of the macromolecules 
that make up its extracellular matrix enable the disc to fulfi ll 
its mechanical role. Fibrillar collagens provide the structural 
framework of the disc (Eyre et al. 1991). The collagen network 
Figure 1. A schematic view of the vertebral joint. Here it is partly cut 
away to show the annulus fi brosus (AF) surrounding the nucleus pulp-
osus (NP) of the intervertebral disc, the cartilaginous endplate (CEP) 
and bony endplate (BEP) interspersed between the disc and vertebral 
body (VB), and the spinal canal (SC) lying behind the vertebral bodies 
and the disc. The spinal canal—surrounded by the discs, the spinal 
processes (SP), and apophyseal joints (AJ)—encloses the spinal cord 
which gives rise to the nerve roots (NR) running adjacent to the poste-
rior portion of the disc. (Adapted from Urban and Roberts 1986).
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of the nucleus is formed from fi ne fi brils of (mainly type-II) 
collagen. Parallel bundles of fi brils (mainly type-I), running 
obliquely between the adjacent vertebral bodies, form the 
concentric lamellae of the annulus (Takeda 1975, Pezowicz 
et al. 2006). The lamellae are held together by elastic proteins 
(Yu et al. 2015), which help to give the disc its fl exibility. 
Aggrecan, the other major macromolecular component, is a 
large polyanionic proteoglycan that imparts a high osmotic 
pressure to the disc matrix (Sivan et al. 2006); the matrix thus 
tends to imbibe water, infl ating the collagen network until the 
osmotic swelling pressure balances the applied load. Apart 
from aggrecan and collagens, the disc matrix also contains a 
large number of other proteins (Figure 2A), which, although 
present in low concentrations, are also important in regulat-
ing the stability and function of the disc matrix (Feng et al. 
2006). 
Disc cells
The human disc contains a small population of resident cells 
(Pattappa et al. 2012) that make and maintain the disc’s mac-
romolecules. The cells also produce proteases that are capable 
of degrading all matrix components. In a healthy disc, the 
rates at which the macromolecules are made and broken down 
are in balance (Figure 2B), but because of the low cell density, 
the turnover in human discs is very slow (Sivan et al. 2014a).
The cell type—and hence the composition—of the matrix 
synthesized varies across the disc and changes with age. The 
nucleus pulposus of all mammals is initially populated by clus-
ters of large notochordal cells that produce a highly hydrated, 
aggrecan-rich, collagen-poor matrix. In humans and in some 
other species, the cell phenotype changes during growth, with 
the notochord cells being replaced by several phenotypically 
distinct but poorly characterized subpopulations of chondro-
cyte-like cells (Molinos et al. 2015). These chondrocyte-like 
cells produce matrix that becomes more collagenous and less 
hydrated during development in humans. In the outer annu-
lus, fi broblast-like cells synthesize the highly organized col-
lagen-rich lamellae. The disc also contains a small number of 
progenitor cells that are potentially able to differentiate into 
the appropriate disc cell phenotypes (Henriksson et al. 2009, 
Sakai et al. 2012, Gruber et al. 2016). Little is known about the 
cells of the cartilage endplate. 
The degenerate disc
Disc degeneration is a loose term that encompasses pro-
gressive biochemical, cellular, and structural changes to the 
disc—with consequent changes in its load-bearing properties. 
Although little is understood about the factors that initiate disc 
degeneration, the process appears to be driven by changes in 
the behavior of its resident cells, which begin to increase the 
production of proteases and reduce production of the matrix 
macromolecules. Hence, macromolecules are degraded and 
lost from the disc at a faster rate than they can be replaced. 
Information on the changes in disc composition and organi-
Figure 2. A. Schematic illustration of assemblies of matrix proteins in the intervertebral disc. Aggrecan monomer is synthesized intracellularly and 
secreted into the ECM where it forms supramolecular aggregates with HA that are stabilized by link proteins. Collagen synthesis involves removal 
of the N- and C-terminal propeptides from procollagen to generate tropocollagen which self-assembles into polymeric collagen fi brils. Cartilage 
oligomeric matrix protein (COMP) acts as a catalyst in collagen fi brillogenesis, and small leucine-rich proteoglycans (SLRPs; e.g. decorin, big-
lycan, fi bromodulin, lumican) and collagen IX regulate fi bril thickness and interfi brillar spacing. CS: chondroitin sulfate;  KS: keratan sulfate; HA: 
hyaluronan; HS-PG, heparan sulfate proteoglycan; MAT: matrilin; PRELP: proline arginine-rich end leucine-rich repeat protein. (Reproduced from 
Feng et al. (2006) with permission). B. Schematic illustration depicting the synthesis and degradation of the disc extracellular matrix. In normal, 
healthy discs, there is a fi ne balance between matrix synthesis, assembly, and turnover, which becomes perturbed during disc degeneration. 
Aggrecanases (ADAMTS-4 and -5) within the ECM cause cleavage and fragmentation of the aggrecan core protein. Degradation of collagen 
fi brils occurs through the activity of collagenases (MMP-1 and -13) and gelatinases (MMP-2 and -9). α5β1: α5β1 integrin (fi bronectin receptor); 
CS: chondroitin sulfate; CD44: hyaluronic acid receptor; G1, G2, and G3: globular domains of aggrecan; GF growth factors: cytokines and other 
bioactive signaling molecules; HA: hyaluronic acid; KS, keratan sulfate. (Reproduced from Sivan et al. (2014a) with permission).
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zation with degeneration has been obtained from examination 
of discs taken at autopsy or removed at surgery (Lyons et al. 
1981, Boos et al. 2002, Roberts et al. 2006). Degenerate discs 
have high concentrations of proteases that tend to degrade the 
macromolecules of the disc, particularly aggrecan—the con-
centration of which falls on disc degeneration (Sivan et al. 
2014b) (Figure 2B); degenerate discs thus retain less water 
and lose it faster under load. As the disc degrades and becomes 
more dehydrated, the lamellae become disorganized and the 
disc loses structural integrity, with formation of fi ssures and 
defects at the bone-disc interface (Figure 3A). The cartilagi-
nous endplate tends to calcify, decreasing nutrient transport 
to the cells; many of them become senescent and die (Kletsas 
2009). Blood vessels and nerves invade the previously avascu-
lar, aneural disc along with infl ammatory cells such as mac-
rophages. The changes seen in disc degeneration vary from 
individual to individual, may start early in life, appear to be 
strongly genetic (Boos et al 2002, Battié et al. 2009), and are 
an ongoing process with the severity and number of degenera-
nance imaging (MRI). It is often classifi ed using MRI scores 
(Pfi rrmann et al. 2001) (Figure 3B), based on changes in disc 
height and signal intensity without considering other degra-
dative features. MRI grade-3 discs, for instance, may include 
discs with very different degrees of endplate irregularity, disc 
bulge, or radial or circumferential tears (Figure 3A). Currently, 
degenerative changes at the tissue and cellular level cannot be 
detected non-invasively. 
What degenerative changes are the biological thera-
pies aimed at repairing?   
Currently, disc cell therapies are mostly aimed at restoring 
macromolecular components, with aggrecan in the nucleus 
being the major focus, as the mechanical consequences of its 
loss are very apparent. However, while desirable mechanical 
properties for repair have been defi ned (Cortes et al. 2014), 
little is known about what other components of the complex 
matrix—apart from collagens—are necessary for functional 
repair. Moreover, while restoration of nucleus hydration is 
 Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
A
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Figure 3. A. Sagittal sections of human lumbar intervertebral discs at various stages of degeneration. 
Features such as height loss, fall in water content,  annular tears, osteophytes, and endplate sclerosis 
observed at different stages of degeneration are indicated (Adapted from Galbursera et al. 2014). 
   B. MRIs showing discs at different stage of Pfi rrmann degeneration grade. Grading is based on signal 
intensity, distinction between nucleus and annulus, degree of homogeneity of disc structure, and loss 
of disc height. Features which are apparent morphologically (Figure 3a), such as fi ssures, changes in 
the endplate and even herniations are not taken into account in this grading scheme (adapted from 
Pfi rrmann et al. 2001)
tive changes increasing with age.
Functional changes in disc degen-
eration
The morphological and bio-
chemical changes resulting from 
disc degeneration infl uence the 
mechanical behavior of the disc, 
and therefore of the whole spinal 
column (Adams 2004, Galbusera 
et al. 2014, Von Forell et al. 2015, 
Muriuki et al. 2016). Degeneration, 
with its loss of aggrecan, results in 
a fall in hydration and a reduction 
in disc height, an increase in disc 
bulge, and a change in stiffness. 
Loss of the integrity of the disc 
results in instability of the spinal 
motion segment, possibly leading 
to spondylolisthesis. Inappropriate 
loads are thus transmitted to other 
spinal structures such as the facet 
joints, which may become osteo-
arthritic—and also to the posterior 
ligaments, which may thicken, 
leading to spinal stenosis. Pro-
found degenerative changes in the 
spinal column triggered by a series 
of these degenerative events may 
end in onset of complex spinal 
deformities. 
Diagnosis of disc degeneration 
in vivo
In vivo, disc degeneration is 
detected using magnetic reso-
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the aim of many studies, fewer studies have examined repair 
of the annulus (Sakai and Grad 2015) or cartilage endplate 
(Bendtsen et al. 2011, Nosikova et al. 2012), yet the integrity 
of these structures is also essential for disc health. Thus, would 
functional and stable cellular disc repair require an approach 
that integrates all disc regions (Nosikova et al. 2012)? 
Cellular repair 
Which cells are appropriate for cellular repair of the 
disc?
It is a challenge to fi nd an appropriate source of cells for disc 
repair (Kregar-Velikonja et al. 2014, Sakai and Andersson 
2015). Human disc cells can only be harvested during sur-
gical procedures. As no autologous cells from healthy discs 
are available, cells from other cartilages have been used for 
animal studies, while the use of notochord cells to stimulate 
resident cells is under investigation (Arkesteijn et al. 2015). 
Most researchers have, however, concentrated on differentiat-
ing stem cells or progenitor cells towards a nucleus pulpo-
sus-like cell type. Many studies have investigated the use of 
autologous mesenchymal stem cells (MSCs); allogenic MSCs 
are being tested in clinical trials (Table). A few studies have 
investigated differentiation of progenitor cells, or embryonic 
or induced pluripotent stem cells, towards the notochord- or 
adult nucleus pulposus cell phenotype. Success in differen-
tiation is judged by expression of phenotypic nucleus pulpo-
sus markers (Risbud et al. 2015), which may not be specifi c 
(Thorpe et al. 2016), and through expression of matrix mac-
romolecules such as collagen II and aggrecan, which are also 
expressed by other cartilages. 
Currently, strategies tend to implant only 1 cell type into 
the disc—albeit that there are different cellular subpopulations 
even in the nucleus—and disc degeneration almost invariably 
involves more than 1 disc region (Figure 3A). Will stem cells 
implanted directly into the disc differentiate into the popula-
tions required to regenerate a stable nucleus, and repair the 
annulus and endplate? Strategies such as the use of notochord 
cells and chondrocyte-like cells generated from human stem 
cells may restore the dialogue between both cell types, based 
on the secretion of growth factors including TGF-β, CTGF, 
and SHH, and lead to the survival of nucleus cells and an 
increase in proteoglycan synthesis (Dahia et al. 2012). Would 
such differentiation strategies be suffi cient, or would each 
region have to be directly targeted with appropriate cells? 
 
Can implanted cells survive and function in the chal-
lenging environment found in degenerate discs? 
As the dense matrix of the cartilaginous endplate and matrix 
of the normal disc acts as a permeability barrier between the 
disc cells and circulating macromolecules, the activity of the 
disc cells is governed to a large extent by their extracellular 
physical environment, and by signals from contacts with the 
extracellular matrix. 
Nutrient levels limit the number of viable cells that can be 
implanted into the disc
Clinical trials of cellular therapies for intervertebral disc repair
  ClinicalTrials.gov
Title Place identifi er Status
Autologous adipose derived stem cell therapy for Bundang CHA Hospital,  NCT02338271 Recruiting
intervertebral disc degeneration  Korea
Treatment of degenerative disc disease with allogeneic Hospital Clinico Universitario,  NCT01860417 Ongoing, not recruiting
mesenchymal stem cells Valladolid, Spain
Autologous adipose tissue derived mesenchymal stem Biostar, Korea University NCT01643681 Unknown
cell transplantation in patient with lumbar intervertebral Anam Hospital
disc degeneration
Safety and preliminary effi cacy study of mesenchymal Mesoblast Ltd. NCT01290367 Completed but no
precursor cells (MPCs) in subjects with lumbar back pain   results posted 
Safety and effi cacy study of rexlemestrocel-L  (viz. allogenic Mesoblast Ltd. NCT02412735 Recruiting
MSCs) in subjects with chronic discogenic lumbar back pain
Lumbar degenerative disc disease treatment with bone Red de Terapia Celular,  NCT02440074 Withdrawn
marrow autologous mesenchymal stem cells (MSV) Spain
Human autograft mesenchymal stem cell mediated Trinity Stem Cell Institution,  NCT02529566 Enrolling by invitation
stabilization of the degnerative lumbar spine Odessa, Florida, USA
Adipose cells for degenerative disc disease Bioheart Inc. NCT02097862 Recruiting
Safety and effi cacy with NOVOCART disc plus (ADCT) for Tetec AG NCT01640457 Ongoing, not recruiting
the treatment of degenerative disc disease in lumbar
spine (NDisc) 
A study comparing the safety and effectiveness of cartilage ISTO Technologies Inc.,  NCT01771471 Ongoing, not recruiting
cells injected into the lumbar disc as compared to a placebo USA
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Extracellular nutrient concentrations are of particular impor-
tance in the avascular disc (Figure 4A) (Grunhagen et al. 
2011), which obtains its energy by aerobic glycolysis. Nutri-
ent levels fall with distance from the blood supply and must 
remain above critical levels (0.2 mM glucose, pH 6.7) for cells 
to remain viable. Although much interest has been expressed 
in the hypoxic environment of the disc and the role of HIF-1 
and HIF-2 (Risbud et al. 2010), nucleus cells can survive with-
out oxygen; even so, they consume it, and matrix synthesis is 
affected by oxygen concentrations. As in other avascular car-
tilages (Stockwell 1971), viable cell density varies inversely 
with disc height, being only 1–5 million cells/mL in healthy 
human lumbar discs but over 50 million cells/mL in mouse 
discs (Figure 4B). 
The supply of nutrients thus limits the number of viable 
cells that can be implanted into even a healthy disc. In degen-
erate discs, calcifi cation of the endplate further restricts nutri-
ent supply and the number of viable cells (Figure 4A). Cells 
implanted into a degenerate disc may therefore have limited 
access to nutrients, compromising their activity and survival. 
 
Signals from the matrix are disturbed in degenerate discs 
Disc cells are sensitive to the level of extracellular osmolarity, 
which is regulated by aggrecan concentrations. Loss of aggre-
can and hence osmolarity in degenerate discs both reduces 
rates of matrix production (Takeno et al. 2007) and initiates 
infl ammatory changes (van Dijk et al. 2015). In addition, cells 
in degenerate discs produce more active proteases (Roberts et 
al. 2000, Pockert et al. 2009), which will tend to work against 
the ability of implanted cells to produce new matrix. 
The infl ammatory environment of degenerate discs can have an 
adverse effect on implanted cells
Infl ammation is almost invariably encountered in degener-
ate discs (Risbud and Shapiro 2014). Infl ammatory cytokines 
upregulate matrix degradation, thus slowing the rates of matrix 
accumulation and hindering attempts at repair; they can also 
induce pain. Moreover, these cytokines lead to further nutri-
tional stresses, increasing rates of glycolysis, and thus further 
reducing glucose levels and pH levels—thereby compromis-
ing the activity and viability of implanted cells (Wuertz et al. 
2009). Infl ammation therefore appears to provide an unfavor-
able environment for implanted cells.   
Can scaffolds drive cells towards repair? 
The highly hydrated networks of hydrogels make them par-
ticularly suitable as a cell support for nucleus regeneration. 
While synthetic scaffolds with mechanical properties match-
ing those of the nucleus are of interest, natural biopolymers 
have advantages in mimicking the native extracellular envi-
ronment regarding mechanical, permeability, and biochemi-
cal properties—and in providing a bioresorbable temporary 
3-dimensional microenvironment. Some, such as injectable 
alginate (Zeng et al. 2015) and hyaluronan hydrogels (Pero-
glio et al. 2013), may optimize stem cell differentiation and 
synthesis of an appropriate extracellular matrix. However, 
there are still no hydrogels that are able to fulfi ll needs regard-
ing both cell biocompatibility and load-bearing capacity, and 
yet can also act as a reservoir of bioactive molecules. 
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Figure 4. A. Schematic illustration showing nutrient pathways in a normal disc (a) and changes seen in disc degeneration (b). Most of the disc is 
supplied with nutrients by diffusion from capillaries arising in the vertebral body, which penetrate the subchondral plate and terminate at the junc-
tion with the cartilage endplate. Nutrients diffuse from these capillaries, through the cartilage endplate and disc matrix to the cells, which, in the 
center of a human disc, may be up to 8 mm from the nearest capillary. Nutrient supply is adversely affected in disc degeneration; disc degeneration 
is associated with atherosclerosis of the lumbar arteries and calcifi cation of the cartilaginous endplate. Loss of nutrient supply leads to a fall in the 
number of active and viable cells that can be supported in the disc. (Reproduced from Huang et al. (2014) with permission). B. The inverse relation-
ship between disc cell density across the nucleus pulposus and disc height. Cell density was measured in histological sections of discs taken from 
mice, rats, rabbits, cats, dogs, pigs, and humans. Here it has been plotted against disc half-height (adapted from Holm and Nachemson  1983).
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Results from animal models may be misleading 
Numerous in vivo studies have examined the process of cellu-
lar repair in animals ranging from mice to larger animals such 
as pigs and goats (Sakai and Andersson 2015), with apparently 
favorable outcomes. However, can such promising results be 
expected in humans? The discs of these animals, even those 
of cattle, are considerably smaller than human lumbar discs 
(Figure 5). The animal discs can consequently support a much 
greater cell density than human discs (Figure 4B). Moreover, 
the animals used are generally young or even immature, with 
degeneration produced by an acute intervention that may 
not produce infl ammatory changes similar to those seen in 
humans, and may leave the nutrient supply unimpaired. Here, 
implanted cells appear to be able to survive and produce repair 
tissue relatively rapidly (in weeks or months). By contrast, the 
half-life of aggrecan in a degenerate human disc is around 4 
years, and that of collagen and elastin is more than 50 years 
(Sivan et al. 2014b). Hence, results from animal models must 
be viewed with caution (Alini et al. 2008).
Which patients would benefi t from disc repair?
The important question of which patients would be suitable 
for cellular therapies has seldom been addressed (Kandel et 
al. 2008, Tibiletti et al. 2014, Benneker et al. 2014, Sakai and 
Andersson 2015). Patients come to see a clinician because 
they have back pain, not because they are worried about disc 
degeneration. Indeed, many people with even severe disc 
degeneration are asymptomatic and are unaware of having 
any spinal problems (Brinjikji et al. 2015). Thus, should pain 
rather than disc degeneration be the clinical target? 
Currently, there is no reliable means of diagnosing whether a 
disc is the source of pain or not; discography has been discred-
ited and may indeed cause harm (Carragee et al. 2009), and 
there are no validated MRI indications. In most cases, it is not 
known whether low back pain even arises from the disc; other 
structures such as the facets may also be involved, so regenerat-
ing the disc alone may not be effective. Moreover neuropathic 
pain, central nervous system changes, and disorders of muscu-
lar control are evident in many back pain patients (Freynhagen 
and Baron 2009, Yu et al. 2014, Schabrun et al. 2015), so even 
complete regeneration of the disc may not cure the pain. 
Summary
Because of the complex nature of degenerative changes, bio-
logical repair of the disc invokes challenges in many areas. An 
integrated approach that involves not only the choice of appro-
priate cells and scaffolds for the different regions of the disc 
(including the endplate), but also targets infl ammation and 
nutrient supply, might be necessary for successful and stable 
repair—and restoration of function. Although small clinical 
studies using single cell populations have been published 
showing apparent success (Meisel et al. 2006, Yoshikawa et al. 
2010, Orozco et al. 2011, Mochida et al. 2015), information 
on outcomes is still awaited from randomized clinical trials 
(Table), which are currently in progress. 
Conclusions
Over the past decade, the growing interest in the development 
of cell therapies has led to real progress with not only some 
promising results in this fi eld in animal studies, but also in fur-
thering our understanding of the biology of the intervertebral 
disc in general. However, a number of biological challenges 
must be overcome before these cellular therapies can be put 
into routine clinical use in humans.
One challenge is to improve characterization of the pheno-
type of the various disc cell populations, and then to deter-
mine how they interact under normal conditions and also in 
the nutrient-poor and infl ammatory environment of degener-
ate discs—and importantly, to characterize the matrix macro-
molecules that they produce at the protein level. Without this 
information, it would be diffi cult to develop rational strategies 
for differentiation of stem or progenitor cells into cell pheno-
types that can survive implantation and produce a stable and 
functional matrix.  
Another challenge is to develop strategies for coping with 
the long repair process (years) in large human discs. This 
might necessitate designing scaffolds that, as well as sup-
porting cells, would be able to restore load-bearing function 
to the degenerate disc and that can be maintained safely in 
the tissue until an appropriate matrix is synthesized by the 
low number of viable cells that are able to survive in human 
lumbar discs. 
Yet another challenge, as in other regenerative cell-based 
Figure 5. Relative sizes of intervertebral discs from different species. 
From left to right: human lumbar L4–L5 disc; bovine tail C1–C2 disc; 
sheep thoracic T11–T12 disc; rat lumbar and tail discs (with arrows 
showing the intervertebral disc location). (Reproduced from Alini et al. 
2008 with permission).
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therapies, is to reduce costs. Currently, the high cost of autolo-
gous donor cell preparations, and regulatory barriers, prevent 
routine clinical application for disorders such as disc degen-
eration. 
Probably the most diffi cult challenge is to improve diagno-
sis in order to determine which patients would benefi t most 
from disc regeneration, remembering that patients seek medi-
cal help for pain, not for disc degeneration. Even though cur-
rent strategies using anti-TNF antibodies to treat pain have not 
always met with success (Cohen et al. 2009, Freeman et al. 
2013), patients might still be better served by developing cel-
lular therapies that are aimed at damping down infl ammation 
and pain (Pettine et al. 2015,Willems et al. 2015), rather than 
through therapies aimed at biological regeneration of the disc.
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